Abstract: A transcriptional regulator specifically responding to D-2-hydroxyglutarate (D-2-HG) and its application in the biological detection of D-2-HG. Wherein the transcriptional regulator is named DhdR and the nucleotide sequence is shown as SEQ ID NO: 1. The D-2-HG biosensors BD2HG-0 and BD2HG-1 are constructed using the transcriptional regulator DhdR and can detect biological samples containing D-2-HG.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody fusion protein thereof.

Abstract: The present disclosure provides a method for sweat volume detection based on sweat print imaging, comprising: obtaining a raw data set, the raw data set including at least one sweat print image formed by dropping different volumes of sweat on a test paper under different environmental parameters; obtaining a color value extreme of the sweat print image and dividing the sweat print image into at least one region; calculating a sweat error based on a total sweat collection volume and a real sweat volume; obtaining a trained error prediction model; obtaining a to-be-tested sweat print image and current environmental parameters; inputting the current environmental parameters and a count of regions of the to-be tested sweat print image into the trained error prediction model to determine a sweat error of the to-be-tested sweat print image; calculating a sweat volume and a sweat rate based on the sweat error.

Abstract: The present disclosure relates to the technical field of genetic engineering, in particular to a target ligand. The target ligand provided by the present disclosure forms a siRNA conjugate with a specific small interfering RNA sequence, which targets to an angiopoietin like 3 (ANGPTL3), and reduce the expression quantity of an ANGPTL3 protein by degrading a transcript of an ANGPTL3 gene in a cell. Therefore, the siRNA conjugate formed by the target ligand provided by the present disclosure may be used to prevent and/or treat a dyslipidemia disease.

Abstract: The present invention discloses a method for calibrating controllable phase shifters in a multi-stage staggered Mach-Zehnder interferometer structure on an optical chip, aiming to solve the problem of calibrating the controllable phase shifters in a configurable optical network of the multi-stage staggered Mach-Zehnder interferometers. The technical solution is to calibrate the controllable phase shifters that can be calibrated in the optical network; and then to constitute calibration conditions for and calibrate inner phase shifters that has not been; and finally to constitute calibration conditions for and calibrate outer phase shifters that is not calibrated.

Abstract: A filter having antibacterial activity is provided. The filter comprises at least one layer of polymer nanofibers and antibacterial particles positioned on or within the at least one layer of polymer nanofibers, wherein the antibacterial particles comprise a quaternary ammonium compound grafted onto a surface of a metal-organic framework. Methods of manufacturing the filter and decontaminating a fluid are also provided.

Abstract: A point-of-interest (POI) information management method includes: obtaining a webpage link; obtaining a webpage text associated with the webpage link; obtaining at least one item of POI information matching the webpage text from a POI information repository; presenting the at least one item of the POI information; in response to a pre-determined operation being performed on a first item of the POI information of the at least one item of the POI information, presenting a route from a current location to an address indicated in the first item of the POI information and a first operable icon; and in response to detecting another pre-determined operation is performed on the first operable icon, setting the route as a target trip.

Abstract: A genetically engineered bacterial strain that produces N-acetylglucosamine, as well as a method of construction and use thereof. The genetically engineered bacterial strain can ferment N-acetylglucosamine under a condition of 40-50° C. Through knocking out genes for glucosamine 6-phosphate deaminase, N-acetylglucosamine-6-phosphate deacetylase and the N-acetylglucosamine transporter protein from a parental bacterium, an N-acetylglucosamine catabolism pathway is blocked. Moreover, overexpression genes for glucosamine 6-phosphate synthase and glucosamine 6-phosphate acetylase are introduced, enabling extra cellular accumulation of N-acetylglucosamine and high-temperature fermentation of N-acetylglucosamine at a temperature higher than 40° C.

Abstract: In a method for making a measurement of the hip in an ultrasound image, an ultrasound image of the hip is obtained. A spatial coherence map associated with one or more lags of the ultrasound waves associated with the ultrasound image is also obtained. Then a quality metric is determined based on the ultrasound image of the hip and the spatial coherence map. The quality metric indicates the suitability of the ultrasound image for making the measurement of the hip. If the quality metric indicates that the ultrasound image is above a threshold quality, then the method then comprises indicating that the ultrasound image is suitable for making the measurement of the hip.

Abstract: A motor vehicle lock comprising a locking mechanism which essentially consists of a rotary latch and a pawl, further comprising a drive and a securing element. The drive acts on the securing element via a toothed rack element that is equipped with a blocking element. According to the invention, the blocking element is in the form of a tilting lever defining at least two end positions of the toothed rack element.

Abstract: Provided are a vehicle monitoring method and a vehicle monitoring system. The vehicle monitoring method includes that: a polarization angle of polarized light in a sky image reflected by a vehicle window in a monitoring scenario is calculated, and a light-filtering polarization angle is calculated according to the polarization angle of the polarized light in the sky image reflected by the vehicle window, where the polarized light in the sky image is formed by scattered sunlight in a sky region corresponding to the sky image; the polarized light in the sky image reflected by the vehicle window in the monitoring scenario is filtered out according to the light-filtering polarization angle; and the monitoring scenario is imaged to form a monitoring image.

Abstract: The present invention provides inhibitors of fucosylation during protein expression from mammalian cells. The inhibitors are derived from rhamnose and act by inhibition of GDP-mannose 4,6-dehydratase (GMD). The invention further provides methods of making proteins with reduced level of fucosylation, such as antibodies and antibodies made by the methods of the present invention. Such hypofucosylated or nonfucosylated antibodies may find use, for example, in treatment of human disease in which is it therapeutically eneficial to direct antibody dependent cellular cytotoxicity (ADCC) mediated killing of cells expressing the antibody target on their surface, for example in depletion of Tregs in cancer patients using a hypofucosylated or nonfucosylated anti-CTLA-4 antibody.

Abstract: Provides an artificial enzyme obtained by improving upon a sequence of a natural nicotine dehydrogenase, wherein the improvement comprises replacing at least one amino acid hindering product release with an amino acid with smaller side chains, thereby improving a catalytic rate.

Abstract: The present invention provides a quinoline derivative for the treatment of nasopharyngeal carcinoma and use thereof in preparation of a pharmaceutical composition for tumor treatment.

Abstract: A transcriptional regulator LhgR is specifically responsive to L-2-hydroxyglutarate (L-2-HG) and an L-2-HG biosensor based on this transcriptional regulator; wherein the biosensor is a fusion protein of cyan fluorescent protein mTFP, L-2-HG specific transcriptional regulator LhgR, and yellow fluorescent protein Venus, including three types of L-2-HG biosensor LHGFR0N0C, LHGFR0N3C, and LHGFR0N7C. The application of the L-2-HG biosensor in the detection of L-2-HG-containing biological samples, real-time detection of intracellular L-2-HG concentration in bacteria and in human cells. The experiments confirmed that the biosensor can achieve high specificity, sensitivity, and accuracy in the detection of L-2-HG and can determine intracellular L-2-HG dynamics in real time, which has good application prospects.

Abstract: A double-channel fluid injection apparatus includes a main shaft, a bearing box, and a sealing box. The main shaft includes an outer tube and an inner tube. An internal channel of the inner tube and a vertical through channel constitute a first fluid passageway. The inner tube and the outer tube form an annular gap, and a channel D is radially formed at a lower part of the outer tube and is in communication with the annular gap, thus constituting a second fluid passageway. The bearing box is mounted on a boss of the outer tube. The sealing box includes a sealing cylinder fixedly connected to a lower end of a lower end cap of the bearing box. A channel E in communication with the second fluid passageway is radially formed at a position of the sealing cylinder corresponding to the channel of the outer tube.

Abstract: Systems, devices, and methods are provided to provide serial monitoring for a patient. An ultrasound system is provided which may include subdividing a portion of the anatomy of a patient into a number of zones. Imaging data may be received by an imaging device. This imaging data may be used to generate a severity score for each zone based on imaging parameters within the imaging data. Changes in the severity score for each zone may be displayed over time, such that a medical professional may monitor each zone in a serial manner.

Abstract: Provided is an application of a compound, 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxy quinolin-7-yl]oxy]methyl]cyclopropylamine, in preparation of a medicament for the treatment of head and neck cancer, and an application of a pharmaceutical composition of the compound combined with a second therapeutic drug in the preparation of a medicament for the treatment of head and neck cancer. The head and neck cancer can also be nasopharyngeal cancer.

Abstract: A combination pharmaceutical composition used for the treatment of small cell lung cancer, comprising: (i) compound I or a pharmaceutically acceptable salt thereof; and (ii) at least one second treatment drug, the chemical name of compound I being 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.